• EGOC · OTC
  • DUSS · OTC
  • CGFIA · OTCQB
  • POTG · OTCQB
  • EMXC · OTC
  • TYTN · OTC
  • TDGI · OTC
  • LUXD · OTCQB
  • NYXO · OTCQB
  • LBAS · OTCQB
  • Biotech Developer Divine Skin (DSKX) Debuts New Hair-Growth Molecule Nanoxidil

    Written by: Dana Salvo

    Bookmark and Share

    DSKXMIAMI BEACH, Fla., Aug. 2, 2011 — Hair-growth developer Divine Skin Inc. (DSKX) introduced a new molecule, Nanoxidil, designed to stimulate follicles at the vertex of the scalp and surpass minoxidil for efficacy and tolerability. The innovative new compound offers unique advantages for penetration and persistence because its molecular weight is lower than that of minoxidil, a chemical on the market for 30 years now.

    “This is a significant step forward in topical therapy, and we are very excited,” said Daniel Khesin, CEO of Divine Skin.

    He added that new products could be brought to market quickly since Nanoxidil did not require health-agency approval in most countries. He anticipated that Divine Skin would see significant revenue from Nanoxidil, which resulted from a five-year research-and-development effort.

    Spectral.DNC-N, part of the DS Laboratories brand, would be the first treatment to employ Nanoxidil 5%, which could eventually succeed minoxidil as the new standard for topical treatment.

    Nanoxidil’s precise mechanism of action is still under study. Researchers expect it to potentiate desirable properties and mitigate side effects, compared to minoxidil. Studies of minoxidil have shown it to open ion channels, induce resting follicles into growth phase, increase follicle size, relax vascular smooth muscle, and stimulate vascular endothelial growth factor. Nanoxidil’s lower molecular weight may boost its absorption properties for greater efficacy.

    “We expect Nanoxidil to become a powerful force in the fight against thinning and shedding hair, working faster and better with enhanced tolerability,” predicted Khesin. “It may allow more patients to maintain their hair, and it may work for patients who have not responded to standard minoxidil therapy.”

    August 2, 2011 @ 11:16 pm Trackback URL Posted in Industry News and tagged with , , , , .